TRIPASS XR تري باس

 

Brambilla P et al. Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer

antidepressants: a meta-analysis of clinical trial data. Pharmacopsychiatry. 2005;38(2):69.

Tourian KA et al. Analysis of the effect of desvenlafaxine on anxiety symptoms associated with major depressive

disorder: pooled data from 9 short-term, double-blind, placebo-controlled trials. CNS Spectr. 2010;15:187.

Pae CU et al. Milnacipran: beyond a role of antidepressant. Clin Neuropharmacol. 2009;32:355.

Asnis GM, Henderson MA. Levomilnacipran for the treatment of major depressive disorder: a review.

Neuropsychiatr Dis Treat. 2015;11:125.

Rickels K et al. Remission of generalized anxiety disorder after 6 months of open-label treatment with venlafaxine

XR. Psychother Psychosom. 2013;82(6):363.

Khan AY, Macaluso M. Duloxetine for the treatment of generalized anxiety disorder: a review. Neuropsychiatr

Dis Treat. 2009;5:23.

Hartford J et al. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and

active-controlled trial. Int Clin Psychopharmacol. 2007;22:167.

Koponen H et al. Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary

care physicians. Prim Care Companion J Clin Psychiatry. 2007;9:100–107.

Rynn M et al. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose,

progressive-titration, placebo-controlled trial. Depress Anxiety. 2008;25:182.

Davidson JR et al. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a

double-blind placebo-controlled trial. Eur Neuropsychopharmacol. 2008;18:673.

Allgulander C et al. A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients

with generalized anxiety disorder. J Psychopharmacol. 2008:22(4):417.

Fawcett J, Barkin RL. A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine

for the treatment of patients with major depression and symptoms of anxiety. J Clin Psychiatry. 1998;59:123.

Gambi F et al. Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study. J

Psychopharmacol. 2005;19:483.

Mahableshwarkara AR et al. A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability

of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder. Hum

Psychopharmacol. 2014;29(1):64.

Bidzan L et al. Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational,

randomized, double-blind, placebo-controlled clinical trial. Eur Neuropsychopharmacol. 2012;22(12):847.

Baldwin DS et alI. Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients

with generalized anxiety disorder. Int Clin Psychopharmacol. 2012;27(4):197.

Rothschild AJ et al. Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week

randomized, double-blind, placebo-controlled clinical trial in the United States. Eur Neuropsychopharmacol.

2012;22(12):858.

Ravindran LN, Stein MB. The pharmacologic treatment of anxiety disorders: a review of progress. J Clin

Psychiatry. 2010;71:839.

Stocchi F et al. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder.

J Clin Psychiatry. 2003;64:250.

Montgomery SA et al. Effectiveness of venlafaxine, extended release formulation, in the short-term and longterm treatment of generalized anxiety disorder: results of a survival analysis. J Clin Psychopharmacol.

2002;22:561.

Mahmood I, Sahajwalla C. Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug.

Clin Pharmacokinet. 1999;36:277.

Apter JT, Allen LA. Buspirone: future directions. J Clin Psychopharmacol. 1999;19:86.

Lydiard RB et al. Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic

symptoms of generalized anxiety disorder. Int J Neuropsychopharmacol. 2010;13:229.

Rickels K et al. Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response

to SSRI or SNRI treatment. Int Clin Psychopharmacol. 2012;27:142.

Frampton JE. Pregabalin: a review of its use in adults with generalized anxiety disorder. CNS Drugs. 2014;28:835.

Feltner D et al. Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol.

2008;23:18.

Montgomery S et al. Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of

safety and tolerability. Curr Med Res Opin. 2013;29(10):1223-30.

Hershenberg R et al. Role of atypical antipsychotics in the treatment of generalized anxiety disorder. CNS Drugs.

2014;28:519.

Ballenger JC. Treatment of anxiety disorders to remission. J Clin Psychiatry. 2001;62(Suppl 12):5.

Trevor AJ. Sedative-hypnotic drugs. In: Katzung BG, Trevor AJ. eds. Basic & Clinical Pharmacology. 13 ed.

New York, NY: McGraw-Hill; 2015. Available at http://accesspharmacy.mhmedical.com/content.aspx?

bookid=1193&Sectionid=69106765. Accessed July 1, 2015.

Klein E. The role of extended-release benzodiazepines in the treatment of anxiety: a risk-benefit evaluation with a

focus on extended-release alprazolam. J Clin Psychiatry. 2002;63(Suppl 14):27.

Liston HL et al. Drug glucuronidation in clinical psychopharmacology. J Clin Psychopharmacol. 2001;21:500.

Gladsjo JA et al. Absence of neuropsychologic deficits in patients receiving long-term treatment with alprazolamXR for panic disorder. J Clin Psychopharmacol. 2001;21: 131.

Zhong G et al. Association between benzodiazepine use and dementia: a meta-analysis. PLoS One.

2015;10(5):e0127836.

Billoti de Gage S et al. Is there really a link between benzodiazepine use and the risk of dementia? Expert Opin

Drug Saf. 2015;14(5):733.

Lauderdale SA, Sheikh JI. Anxiety disorders in older adults. Clin Geriatr Med. 2003;19:721.

Meuleners LB, Duke J, Lee AH, et al. Psychoactive medications and crash involvement requiring hospitalization

for older drivers: a population-based study. J Am Geriatr Soc. 2011;59(9):1575.

Huang AR et al. Medication-related falls in the elderly: causative factors and preventive strategies. Drugs Aging.

2012;29(5):359.

Ensrud KE et al. Central nervous system-active medications and risk for falls in older women. J Am Geriatr Soc.

2002;50:1629.

Wang PS et al. Hazardous benzodiazepines regimens in the elderly: effects of half-life, dosage, and duration on

risk of hip fracture. Am J Psychiatry. 2001;158:892.

Toblin RL, Paulozzi LJ, Logan JE, et al. Mental illness and psychotropic drug use among prescription drug

overdose deaths: a medical examiner chart review. J Clin Psychiatry. 2010;71(4):491.

Rothschild AJ et al. Comparison of the frequency of behavioral disinhibition on alprazolam, clonazepam, or no

benzodiazepine in hospitalized psychiatric patients. J Clin Psychopharmacol. 2000;20:7.

Mancuso CE et al. Paradoxical reactions to benzodiazepines: literature review and treatment options.

Pharmacotherapy. 2004;24(9):1177.

Posternak MA, Mueller TI. Assessing the risks and benefits of benzodiazepines for anxiety disorders in patients

with a history of substance abuse or dependence. Am J Addict. 2001;10:48.

Rickels K et al. Pharmacologic strategies for discontinuing benzodiazepine treatment. J Clin Psychopharmacol.

1999;19(Suppl 2):12S.

Lader M et al. Withdrawing benzodiazepines in primary care. CNS Drugs. 2009;23:19.

Davidson JR et al. A psychopharmacological treatment algorithm for generalized anxiety disorder (GAD). J

Psychopharm. 2010;24(1):3.

Donovan MR et al. Comparative efficacy of antidepressants in preventing relapse in anxiety disorders—a metaanalysis. J Affect Disord. 2010;123(1–3):9.

Askgaard G et al. Phenobarbital compared to benzodiazepines in alcohol withdrawal treatment: a register-based

.

.

cohort study of subsequent benzodiazepines use, alcohol recidivism, and mortality. Drug Alcohol Depend.

2016;161:258.

Tanaka E. Clinically significant pharmacokinetic drug interactions with benzodiazepines. J Clin Pharm Ther.

1999;24:347.

Yasui N et al. Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of

alprazolam. Psychopharmacology (Berl). 1998;139:269.

Pigott TA. Gender differences in the epidemiology and treatment of anxiety disorders. J Clin Psychiatry. 1999;60

(Suppl 18):4.

Stoehr GP et al. Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics. Clin

Pharmacol Ther. 1984;36:683.

Zevin S, Benowitz NL. Drug interactions with tobacco smoking: an update. Clin Pharmacokinet. 1999;36:425.

ACOG Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin: Clinical management guidelines

for obstetrician-gynecologists number 92, April 2008(replaces practice bulletin number 87, November 2007).

Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol. 2008;111:1001.

Wikner BN et al. Use of benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital

malformations. Pharmacoepidemiol Drug Saf. 2007;16:1203.

Bellantuono C et al. Benzodiazepine exposure in pregnancy and risk of major malformations: a critical overview.

Gen Hosp Psychiatry. 2013;35(1):3.

Reis M1, Källén B. Combined use of selective serotonin reuptake inhibitors and sedatives/hypnotics during

pregnancy: risk of relatively severe congenital malformations or cardiac defects. A register study. BMJ Open.

2013 Feb 19;3(2).

National Institute for Health and Care Excellence. Antenatal and postnatal mental health: clinical management

and service guidance. December 2014. http://www.nice.org.uk/guidance/cg192. Accessed July 6, 2015.

Iqbal MM et al. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant.

Psychiatr Serv. 2002;53(1):39.

O’Hara MW, Wisner KL. Perinatal mental illness: definition, description, and aetiology. Best Pract Res Clin

Obstet Gynaecol. 2014;28(1):3.

Kelly LE et al. Neonatal benzodiazepine exposure during breastfeeding. J Pediatr. 2012;161(3):448.

LactMed: Drugs and lactation database. http://toxnet.nlm.nih.gov. Accessed July 6, 2015.

Weinbroun AA et al. A risk-benefit assessment of flumazenil in the management of benzodiazepines overdose.

Drug Saf. 1997;17:181.

Mathieu-Nolf M et al. Flumazenil use in an emergency department: a survey. J Toxicol Clin Toxicol. 2001;39:15.

Penninga E et al. Adverse events associated with flumazenil treatment for the management of suspected

benzodiazepine intoxication - a systematic review with meta-analyses of randomised trials. Basic Clin

Pharmacol Toxicol. 2015. doi: 10.1111/bcpt.12434.

Herman RJ, Wilkinson GR. Disposition of diazepam in young and elderly subjects after acute and chronic dosing.

Br J Clin Pharmacol. 1996;42:147.

Kaplan GB et al. Single-dose pharmacokinetics and pharmacodynamics of alprazolam in elderly and young

subjects. J Clin Pharmacol. 1998;38:14.

Matzke GR, Frye RF. Drug administration in patients with renal insufficiency: minimising renal and extrarenal

toxicity. Drug Saf. 1997;16:205.

Wan J et al. The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation

phenotype. Br J Clin Pharmacol. 1996;42:471.

Yonkers KA et al. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication.

Am J Psychiatry. 1992;149:587.

Chetty M et al. Sex differences in the clearance of CYP3A4 substrates: exploring possible reasons for the

substrate dependency and lack of consensus. Curr Drug Metab. 2012;13(6):778.

Kurose K et al. Population differences in major functional polymorphisms of

pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical

trials for novel drug development. Drug Metab Pharmacokinet. 2012;27(1):9.

Pecknold JC. A risk-benefit assessment of buspirone in the treatment of anxiety disorders. Drug Saf.

1997;16:118.

Dimitriou EC et al. Buspirone vs. alprazolam: a double-blind comparative study of their efficacy, adverse effects

and withdrawalsymptoms. Drug Invest. 1992;4:316.

Delle Chiaie R et al. Assessment of the efficacy of buspirone in patients affected by generalized anxiety

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

disorder, shifting to buspirone from prior treatment with lorazepam: a placebo-controlled, double-blind study. J

Clin Psychopharmacol. 1995;15:12.

Uhlenhuth EH et al. International study of expert judgment on therapeutic use of benzodiazepines and other

psychotherapeutic medications: IV Therapeutic dose dependence and abuse liability of benzodiazepines in the

long-term treatment of anxiety disorders. J Clin Psychopharmacol. 1999;19(Suppl 2):23S.

Sramek JJ et al. Meta-analysis of the safety and tolerability of two dose regimens of buspirone in patients with

persistent anxiety. Depress Anxiety. 1999;9:131.

Grant BF et al. Epidemiology of DSM-5 alcohol use disorder: results from the national epidemiologic survey on

alcohol and related conditions III. JAMA Psychiatry. 2015;72(8):757.

Roy-Byrne PP et al. Panic disorder. Lancet. 2006;368: 1023.

Roy-Byrne PP et al. Panic disorder in the primary care setting: comorbidity, disability, service utilization, and

treatment. J Clin Psychiatry. 1999;60:492.

Andersch S. Hetta J. A 15-year follow-up study of patients with panic disorder. Eur J Psychiatry. 2003;18:401.

Katon WJ. Cllinical practice. Panic disorder. N EnglJ Med. 2006;354(22):2360.

Cousins MS et al. GABA(B) receptor agonists for the treatment of drug addiction: a review of recent findings.

Drug Alcohol Depend. 2002;65:209.

Hasler G et al. Altered cerebral y-aminobutyric acid type-A-benzodiazepine receptor binding in panic disorder

determined by [

11C]flumazenil positron emission tomography. Arch Gen Psychiatry. 2008;65:1166.

Perna G et al. Antipanic drug modulation of 35% CO2

hyperreactivity and short-term treatment outcome. J Clin

Psychopharmacol. 2002;22:300.

Work Group on Panic Disorder et al. Treatment of Patients with Panic Disorder. 2nd ed. Available at

http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/panicdisorder.pdf.

Accessed August 10, 2015.

Bandelow B et al. World federation of societies of biological psychiatry (WFSBP) guidelines for the

pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision.

World J Biol Psychiatry. 2008;9(4):248.

Zamorski MA, Albucher RC. What to do when SSRIs fail: eight strategies for optimizing treatment of panic

disorder. Am Fam Physician. 2002;66:1477.

Lydiard RB. The role of GABA in anxiety disorders. J Clin Psychiatry. 2003;64(Suppl 3):21.

Lepola U et al. Sertraline versus imipramine treatment of comorbid panic disorder and major depressive

disorder. J Clin Psychiatry. 2003;64:654.

Caillard V et al. Comparative effect so flow and high doses of clomipramine and placebo in panic disorder: a

double-blind controlled study. French University Antidepressant Group. Acta Psychiatr Scand. 1999;99:51.

van Apeldoorn FJ et al. Is a combined therapy more effective than either CBT or SSRI alone? Results of a

multicenter trial on panic disorder with or without agoraphobia. Acta Psychiatr Scand. 2008;117:260.

Kampman M et al. A randomized, double-blind, placebo-controlled study of the effects of adjunctive paroxetine

in panic disorder patients unsuccessfully treated with cognitive-behavioral therapy alone. J Clin Psychiatry.

2002; 63:772.

Dannon PN et al. Comorbid cannabis use and panic disorder: short term and long term follow-up study. Hum

Psychopharmacol. 2004;19:97.

Bricker JB et al. Does occasional cannabis use impact anxiety and depression treatment outcomes?: results from

a randomized effectiveness trial. Depress Anxiety. 2007;24: 392.

Muller JE et al. Anxiety and medical disorders. Curr Psychiatry Rep. 2005;7:245.

Bruce SE et al. Are benzodiazepines still the medication of choice for patients with panic disorder with or

without agoraphobia? Am J Psychiatry. 2003;160:1432.

Ruscio AM et al. Social fears and social phobia in the USA: results from the national comorbidity survey

replication. Psychol Med. 2008;38:15.

Pollack MH. Comorbidity, neurobiology, and pharmacotherapy of social anxiety disorder. J Clin Psychiatry.

2001; 62(Suppl 12):24.

Stein MB, Kean YM. Disability and quality of life in social phobia: epidemiologic findings [published correction

appears in Am J Psychiatry. 2000;157:2075]. Am J Psychiatry. 2000;157:1606.

Arbelle S et al. Relation of shyness in grade school children to the genotype for the long form of the serotonin

transporter promoter region polymorphism. Am J Psychiatry. 2003;160:671.

Mathew SJ et al. Neurobiological mechanisms of social anxiety disorder. Am J Psychiatry. 2001;158:1558.

129.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

148.

.

.

.

.

.

154.

.

.

.

.

Schneier FR et al. Low dopamine D2 receptor binding potential in social phobia. Am J Psychiatry. 2000;157:

457.

Freitas-Ferrari MC et al. Neuroimaging in social anxiety disorder: a systematic review of the literature. Prog

Neuropsychopharmacol Biol Psychiatry. 2010;34:565.

Iza M et al. Probability and predictors of first treatment contact for anxiety disorders in the United States:

analysis of data from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). J Clin

Psychiatry. 2013;74(11):1093.

Davidson JRT. Pharmacotherapy of social anxiety disorder: what does the evidence tell us? J Clin Psychiatry.

2006;67(Suppl 12):20.

Simon NM et al. Duloxetine for the treatment of generalized social anxiety disorder: a preliminary randomized

trial of increased dose to optimize response. CNS Spectr. 2010;15:367.

Stein DJ et al. A 2010 evidence-based algorithm for the pharmacotherapy of social anxiety disorder. Curr

Psychiatry Rep. 2010;12:471.

Liebowitz MR et al. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the

treatment of generalized social anxiety disorder. J Clin Psychiatry. 2002;63:66.

Stein DJ et al. Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebocontrolled paroxetine trials. J Clin Psychiatry. 2002;63:152.

Pollack MH et al. A double-blind randomized controlled trial of augmentation and switch strategies for refractory

social anxiety disorder. Am J Psychiatry. 2014;171(1):44.

Feltner DE et al. Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebocontrolled, fixed-dose study. Int Clin Psychopharmacol. 2011;26:213.

Fedoroff IC, Taylor S. Psychological and pharmacological treatments of social phobia: a meta-analysis. J Clin

Psychopharmacol. 2001;21:311.

Shalev AY. Posttraumatic stress disorder and stress-related disorders. Psychiatr Clin North Am. 2009;32:687.

Breslau N. The epidemiology of posttraumatic stress disorder: what is the extent of the problem? J Clin

Psychiatry. 2001;62(Suppl 17):16.

Ballenger JC et al. Consensus statement on posttraumatic stress disorder from the International Consensus

Group on Depression and Anxiety. J Clin Psychiatry. 2000; 61(Suppl 5):60.

American Psychiatric Association. Practice Guideline for the Treatment of Patients with Acute Stress Disorder

and Posttraumatic Stress Disorder. Arlington, VA: American Psychiatric Association; 2004.

Breslau N. Outcomes of posttraumatic stress disorder. J Clin Psychiatry. 2001;62(Suppl 17):55.

Jacobsen LK et al. Substance use disorders in patients with posttraumatic stress disorder: a review of the

literature. Am J Psychiatry. 2001;158:1184.

Krysinska K, Lester D. Post-traumatic stress disorder and suicide risk: a systematic review. Arch Suicide Res.

2010;14(1):1.

Edmondson D et al. Posttraumatic stress disorder and risk for coronary heart disease: a meta-analytic review.

Am Heart J. 2013;166(5):806.

Tran JK et al. Sexual dysfunction in veterans with post-traumatic stress disorder. J Sex Med 2015;12(4):847.

Motzkin JC, Koenigs MR. Post-traumatic stress disorder and traumatic brain injury. Handb Clin Neurol.

2015;128:633.

Davidson JRT. Recognition and treatment of posttraumatic stress disorder. JAMA. 2001;286:584.

Nutt DJ, Malizia AL. Structural and functional brain changes in posttraumatic stress disorder. J Clin Psychiatry.

2004;65(Suppl 1):11.

Koob GF. Corticotrophin-releasing factor, norepinephrine, and stress. Biol Psychiatry. 1999;46:1167.

Southwick SM et al. Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress

disorder. Biol Psychiatry. 1999;46:1192.

Friedman MJ. Future pharmacotherapy for post-traumatic stress disorder: prevention and treatment. Psychiatr

Clin North Am. 2002;25:427.

Ravindran LN, Stein MB. Pharmacotherapy of PTSD: premises, principles, and priorities. Brain Res. 2009;1293:

24.

Thomaes K et al. Can pharmacological and psychological treatment change brain structure and function in

PTSD? A systematic review. J Psychiatr Res. 2014;50:1.

Voisey J et al. Progress towards understanding the genetics of posttraumatic stress disorder. J Anxiety Disord.

2014;28(8):873.

National Institute for Clinical Excellence (NICE). National Clinical Practice Guideline Number 26. Post-

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

186.

.

.

.

Traumatic Stress Disorder (PTSD): The Management of PTSD in Adults and Children in Primary and

Secondary Care. London, UK: National Institute for Clinical Excellence; 2005.

Stein DJ et al. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev.

2006;(1): CD002795.

Amos T et al. Pharmacologic interventions for preventing post-traumatic stress disorder (PTSD). Cochrane

Database Syst Rev. 2014 Jul 8;7:CD006239

Ipser JC, Stein DJ. Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD). Int J

Neuropsychopharmacol. 2012 Jul;15(6):825.

Robert S et al. Open-label trial of escitalopram in the treatment of posttraumatic stress disorder. J Clin

Psychiatry. 2006;67:1522.

Walderhaug E et al. Effects of duloxetine in treatment-refractory men with posttraumatic stress disorder.

Pharmacopsychiatry 2010:43:45.

Villarreal G et al. Duloxetine in military posttraumatic stress disorder. Psychopharmacol Bull. 2010;43(3):26.

Asnis GM et al. SSRIs versus non-SSRIs in post-traumatic stress disorder: an update with recommendations.

Drugs. 2004;64:383.

Warner CH et al. Identifying and managing posttraumatic stress disorder. Am Fam Physician. 2013;88(12):827.

Krystal JH et al. Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military

service-related PTSD: a randomized trial. JAMA. 2011;306(5):493.

Han C et al. The potential role of atypical antipsychotics for the treatment of posttraumatic stress disorder. J

Psychiatr Res. 2014;56:72.

Boehnlein JK, Kinzie JD. Pharmacologic reduction of CNS noradrenergic activity in PTSD: the case for

clonidine and prazosin. J Psychiatr Pract. 2007;13:72.

Koola MM et al. High-dose prazosin for the treatment of post-traumatic stress disorder. Ther Adv

Psychopharmacol. 2014;4(1):43.

Argolo FC et al. Prevention of posttraumatic stress disorder with propranolol: a meta-analytic review. J

Psychosom Res. 2015;79(2):89.

Davidson JR. Long-term treatment and prevention of posttraumatic stress disorder. J Clin Psychiatry.

2004;65(Suppl 1): 44.

Motraghi TE et al. Virtual reality exposure therapy for the treatment of posttraumatic stress disorder: a

methodological review using CONSORT guidelines. J Clin Psychol. 2014 Mar;70(3):197.

Karsen EF et al. Review of the effectiveness of transcranial magnetic stimulation for post-traumatic stress

disorder. Brain Stimul. 2014;7(2):151.

Hetrick SE et al. Combined pharmacotherapy and psychological therapies for post traumatic stress disorder

(PTSD). Cochrane Database Syst Rev. 2010;(7):CD007316.

Talbot LS et al. Cognitive behavioral therapy for insomnia in posttraumatic stress disorder: a randomized

controlled trial. Sleep. 2014;37(2):327.

Pauls DL et al. Obsessive-compulsive disorder: an integrative genetic and neurobiological perspective. Nat Rev

Neurosci. 2014;15(6):410.

Altshuler LL et al. Course of mood and anxiety disorders during pregnancy and the postpartum period. J Clin

Psychiatry. 1998:59(Suppl 2):29.

American Psychiatric Association. Practice Guideline for the Treatment of Patients with Obsessive-Compulsive

Disorder. Arlington, VA: American Psychiatric Association; 2007.

Hollander E. Obsessive-compulsive disorder: the hidden epidemic. J Clin Psychiatry. 1997;58(Suppl 12):3.

Stein DJ. Obsessive-compulsive disorder. Lancet. 2002;360:397.

Rosario-Campos MC et al. Adults with early-onset obsessive-compulsive disorder. Am J Psychiatry.

2001;158:1899.

Phillips KA. The obsessive-compulsive spectrums. Psychiatr Clin North Am. 2002;25:791.

Nestadt G et al. A family study of obsessive-compulsive disorder. Arch Gen Psychiatry. 2000;57:358.

Melke J. Serotonin transporter gene polymorphisms and mental health. Curr Opin Psychiatry. 2003;16:215.

Pato MT et al. Recent findings in the genetics of OCD. J Clin Psychiatry. 2002;63(Suppl 6):30.

Leckman JF, Kim Y-S. A primary candidate gene for obsessive-compulsive disorder. Arch Gen Psychiatry.

2006;63:717.

da Rocha FF et al. Obsessive-compulsive disorder and immunology: a review. Neuropsychopharmacol Biol

Psychiatry. 2008;32:1139.

Blier P et al. Pharmacotherapies in the management of obsessive-compulsive disorder. Can J Psychiatry.

.

.

.

.

.

.

.

.

.

199.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

214.

2006;51:417.

Dell’Osso B et al. Diagnosis and treatment of obsessive-compulsive disorder and related disorders. Int J Clin

Pract. 2007;61:98.

Dell’Osso B et al. Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive

review of their clinical efficacy. Hum Psychopharmacol. 2010;25:17.

National Institute for Health and Care Excellence (NICE). Obsessive-compulsive disorder: core interventions in

the treatment of obsessive-compulsive disorder and body dysmorphic disorder. NICE clinical guideline 31.

Available at http://www.nice.org.uk/cg31. Accessed August 11, 2015.

Jermain DM, Crismon ML Pharmacotherapy of obsessive-compulsive disorder. Pharmacotherapy.

1990;10(3):175.

Ackerman DL, Greenland S. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive

disorder. J Clin Psychopharmacol. 2002;22:309.

Hollander E et al. Refractory obsessive-compulsive disorder:state-of-the-art treatment. J Clin Psychiatry. 2002;

63(Suppl 6):20.

Dold M et al. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessivecompulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials. Int J

Neuropsychopharmacol. 2015;18(9):1.

Abdel-Ahad P, Kazour F. Non-antidepressant pharmacological treatment of obsessive-compulsive disorder: a

comprehensive review. Curr Clin Pharmacol. 2013;8(4):1.

Dold M et al. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessivecompulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. Int J

Neuropsychopharmacol. 2013;16(3):557.

Bloch MH et al. A systematic review: antipsychotic augmentation with treatment refractory obsessivecompulsive disorder. Mol Psychiatry. 2006;11(7):622.

Komossa K et al. Second-generation antipsychotics for obsessive-compulsive disorder. Cochrane Database Syst

Rev. 2010;8(12):CD008141.

Savas HA et al. Quetiapine and ziprasidone as adjuncts in treatment-resistant obsessive-compulsive disorder: a

retrospective comparative study. Clin Drug Invest. 2008;28(7):439.

Storch EA et al. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake

inhibitor-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2013;74(6):e527.

Foa EB et al. Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with

exposure and response prevention or risperidone in adults with obsessive-compulsive disorder. J Clin

Psychiatry. 2015;76(4):440.

Simpson HB et al. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in

obsessive-compulsive disorder: a randomized clinical trial. JAMA Psychiatry. 2013;70(11):1190.

Wang HR et al. Potential role of anticonvulsants in the treatment of obsessive-compulsive and related disorders.

Psychiatry Clin Neurosci. 2014;68(10):723.

Hollander E et al. A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder. World

J Biol Psychiatry. 2003;4(1):30.

Ong CW, Clyde JW, Bluett EJ, et al. Dropout rates in exposure with response prevention for obsessivecompulsive disorder: What do the data really say? J Anxiety Disorder. 2016;40:8.

Dougherty DD et al. Prospective long-term follow-up of 44 patients who received cingulotomy for treatmentrefractory obsessive-compulsive disorder. Am J Psychiatry. 2002;159:269.

Greenberg BD et al. Invasive circuitry-based neurotherapeutics: stereotactic ablation and deep brain stimulation

for OCD. Neuropsychopharmacology. 2010;35;317.

Hamani C et al. Deep brain stimulation for obsessive-compulsive disorder: systematic review and evidencebased guideline sponsored by the American Society for Stereotactic and Functional Neurosurgery and the

Congress of Neurological Surgeons (CNS) and endorsed by the CNS and American Association of

Neurological Surgeons. Neurosurgery. 2014;75(4):327.

Attiullah N et al. Clinical features of obsessive-compulsive disorder. Psychiatr Clin North Am. 2000;23:469.

Hollander E et al. Pharmacotherapy for obsessive-compulsive disorder. Psychiatr Clin North Am. 2000;23:643.

Pampaloni I et al. High-dose selective serotonin reuptake inhibitors in OCD: a systematic retrospective case

notes survey. J Psychopharmacol. 2010;24(10):1439.

Ninan PT et al. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive

disorder: a multicenter double-blind trial. J Clin Psychiatry. 2006;67:15.

.

.

.

.

.

.

.

.

.

.

.

.

Rabinowitz I et al. High-dose escitalopram for the treatment of obsessive-compulsive disorder. Int Clin

Psychopharmacol. 2008;23:49.

Horwath E, Weissman MM. The epidemiology and cross-national presentation of obsessive-compulsive disorder.

Psychiatr Clin North Am. 2000;23:493.

Koran LM et al. Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder. Am J

Psychiatry. 2002;159:88.

Nielsen KK et al. Single-dose kinetics of clomipramine: relationship to the sparteine and s-mephenytoin oxidation

polymorphisms. Clin Pharmacol Ther. 1994;55:518.

Nissen D et al. Mosby’s Drug Consult. 13th ed. St. Louis, MO: Mosby; 2003.

Nielsen K et al. The biotransformation of clomipramine in vitro, identification of the cytochrome P450s

responsible for the separate metabolic pathways. J Pharmacol Exp Ther. 1996;277:1659.

Oesterheld J, Kallepalli BR. Grapefruit juice and clomipramine: shifting metabolic ratios. J Clin

Psychopharmacol. 1997;17:62.

Shimoda K et al. Pronounced differences in the disposition of clomipramine between Japanese and Swedish

patients. J Clin Psychopharmacol. 1999;19:393.

Balant-Gorgia AE, Gex-Fabry M, and Balant LP. Clinical pharmacokinetics of clomipramine. Clin

Pharmacokinet. 1991;20(6):447-62.

Nemeroff CB et al. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry. 1996;153:311.

Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 1998;18:84.

Andrade C. Augmenting selective serotonin reuptake inhibitors with clomipramine in obsessive-compulsive

disorder: benefits and risks. J Clin Psychiatry. 2013;74(12):e1128.

p. 1761

INSOMNIA AND RESULTING DAYTIME SLEEPINESS

Asking the right questions to investigate the type of insomnia (i.e.,

trouble falling asleep, staying asleep, or early morning awakening),

possible causes (lifestyle issues, drugs), resulting impairment, and

concomitant conditions are essential to determine proper management.

Case 84-1 (Questions 1, 2)

Table 84-1, 84-4,

Figure 84-2

Nonpharmacologic treatments such cognitive-behavioral interventions

are recommended first-line therapy for managing insomnia in a variety

of patients owing to high efficacy and avoidance of medication side

effects.

Case 84-1 (Questions 3, 4)

Table 84-2

Pharmacologic treatments for insomnia are selected based on their

efficacy, tolerability, onset and duration of effect, potential for next-day

hangover, and abuse potential.

Case 84-1 (Questions 5–10)

Table 84-3

Insomnia concurrent with medical illness is frequently chronic (>1

month) and, if left untreated, may affect recovery from the medical

condition. Treating both conditions at the same time is recommended.

Case 84-2 (Questions 1–4)

Table 84-5,

Figure 84-2

Insomnia concurrent with psychiatric illness requires optimization of

psychiatric maintenance medications and the judicious use of hypnotic

medications based on type of sleep complaint and substance abuse

history.

Case 84-3 (Questions 1–4)

Figure 84-2

Managing insomnia in an elderly individual involves consideration of agerelated pharmacodynamic and pharmacokinetic changes and counseling

regarding realistic treatment expectations. Medication doses lower than

those used in younger individuals should be prescribed.

Case 84-4 (Questions 1–5)

Table 84-3

If nonpharmacologic treatment is ineffective, diphenhydramine is

considered safe for short-term use (<1 week) in pregnancy. Risks

outweigh benefits for benzodiazepines and nonbenzodiazepine receptor

agonists in pregnancy.

Case 84-5 (Question 1)

SLEEP APNEA

Sleep apnea leads to excessive daytime sleepiness, fatigue, and

increased risk of cardiovascular and cerebrovascular disease. Effective

Case 84-6 (Questions 1, 2)

treatment with continuous positive airway pressure or surgical

interventions can decrease cardiovascular disease and improve overall

functioning and quality of life.

It is essential to avoid sedating medications in patients with sleep apnea

because these agents interfere with mini-arousals that keep the patient

alive.

Case 84-6 (Question 3)

NARCOLEPSY

Narcolepsy is an incurable neurologic disease characterized by sleep

attacks and cataplexy. Stimulants modafinil or armodafinil help decrease

sleep attacks and promote daytime alertness but do not help with

cataplexy or nocturnal insomnia.

Case 84-7 (Questions 1, 2)

Sodium oxybate is effective for cataplexy and improves nocturnalsleep,

but it has high abuse potential and has been associated with psychiatric

side effects.

Case 84-7 (Questions 3, 4)

p. 1762

p. 1763

OVERVIEW

Approximately one-third of the adult life is expended on sleep. The innate necessity

of sleep is present in almost all mammals, though all the functions of sleep are not

fully understood.

1,2 Naturally with human physiology devoted to sleep and the

numerous factors that can disrupt this process, sleep disorders are remarkably

common. Sleep deficiency, including insufficient sleep duration, irregular timing of

sleep, poor sleep quality, and sleep or circadian rhythm disorders, is highly

prevalent and threaten public safety.

3,4 Decades of scientific findings associate sleep

deficiency with increased disease risk, including cardiovascular and metabolic

disease, psychiatric illness, substance abuse, pregnancy complications, and impaired

neurobehavioral and cognitive impairment.

4,5 At least 10% of the American

population is reported to suffer from a sleep disorder that is clinically significant and

of public health concern.

3 Major sleep disorders in the United States include

insomnia ranging from 15% to 35%,

6,7 sleep apnea at 6% to 24%8,9 periodic limb

movements in sleep (PLMS, previously known as nocturnal myoclonus), and restless

leg syndrome (RLS) ranging from 3% to 15%,

10,11 and narcolepsy at 0.025% to

0.05%.

12 Untreated sleep disorders, including chronic insomnia, sleep apnea, PLMS,

and narcolepsy, are all associated with diminished mental and physical functioning

and poor quality of life.

3,4,7

Nightmares, nocturnal leg cramps, and snoring are more benign sleep disorders.

Nightmares occur in 5% to 30% of children 3 to 6 years of age, and approximately

2% to 6% of adults have weekly nightmares.

13 Sleepwalking occurs in 1% to 2% of

the population. Complex sleep behavior disorders, such as driving or eating while

still half asleep, are uncommon to rare. These behaviors are more common in people

taking hypnotics, and medication counseling should be provided for patients

prescribed any sleep medication.

13,14

CIRCADIAN RHYTHM AND SLEEP CYCLES

Sleep is a dynamic process with a cyclical recurrence and varying stages. The

endogenous sleep–wake pattern of humans is based on the solar day–night cycle

called the circadian rhythm. Circadian rhythm is controlled both by internal and

external factors and sets the sleep–wake cycle at 24.2 hours. Sensory input (visual

and acoustic) or other external factors modify the “internal clock” to a 24 hour day

through working with the internal network and signaling brain centers to either wake

or sleep. Thus, darkness is a visual cue that prepares the brain for sleep. Similarly,

bright light serves to prepare the brain for wakefulness.

1,2

Once sleep is initiated, it alternates between the two phases of rapid eye

movement (REM) and nonrapid eye movement (NREM) sleep. These phases vary in

length throughout the sleep cycles. During a normal night of sleep, a person generally

has four to six cycles of sleep which last an average of 90 minutes (vary 70–120

minutes).

15 See Figure 84-1 for normal sleep cycles by age.

Polysomnography

Each sleep stage serves a physiologic function and can be monitored in sleep

laboratories by polysomnography (PSG). PSG is the term used to describe three

electrophysiologic measures: the electroencephalogram (EEG), the electromyogram,

and the electrooculogram of each eye. It may also include an electrocardiogram, air

thermistors, abdominal and thoracic strain belts, and oxygen saturation monitoring.

The pattern of brain waves, muscle tone, and eye movements measured can be used

to categorize the various sleep stages.

15,16

Figure 84-1 Normalsleep cycles.

Nonrapid Eye Movement Sleep

NREM sleep is divided into four stages, with different quantities of time and

functions in each stage. Stage 1 is a transition between sleep and wakefulness known

as relaxed wakefulness, which generally makes up approximately 2% to 5% of sleep.

The function of stage 1 is to initiate sleep. Approximately 50% of total sleep time is

spent in stage 2, which is rapid-wave (theta) or lighter sleep. Stage 2 provides rest

for the muscles and brain through muscle atonia and low-voltage brain wave activity.

Arousability from sleep is highest during stages 1 and 2. Stages 3 and 4 are slowwave (delta) or deep sleep. Stage 3 occupies an average of 5% of sleep time,

whereas stage 4 constitutes 10% to 15% of sleep time in young, healthy adults. In

contrast to stages 1 and 2, it is difficult to awaken someone during stages 3 and 4, or

delta sleep.

15 Delta sleep, also known as restorative sleep, is enhanced by serotonin,

adenosine, cholecystokinin, and IL-1. The ability of IL-1 to promote slow-wave

sleep supports a widely held theory linking deep sleep to the augmentation of immune

function. Some hormones (e.g., somatostatin, growth hormone) are released mainly

during slow-wave sleep. Deep sleep is most abundant in infants and children and

tends to level off at approximately 4 hours a night during adolescence. At age 65,

deep sleep accounts for only 10% of sleep, and at age 75, it is often nonexistent.

1,15–17

Rapid Eye Movement Sleep

Whereas NREM sleep is necessary for rest and rejuvenation, the purpose of REM

sleep remains a mystery. REM sleep is greatest in infants, accounting for about 50%

of total sleep time. As aging occurs before 2 years and throughout adulthood, REM

sleep is usually 20% to 25% of sleep. This percentage of total REM sleep

p. 1763

p. 1764

is maintained into healthy old age, but can decline markedly in the presence of

organic brain dysfunctions of the elderly. REM sleep is also called paradoxical sleep

because it has aspects of both deep sleep and light sleep. Body and brainstem

functions appear to be in a deep sleep state as muscle and sympathetic tone drop

dramatically. In contrast, neurochemical processes and higher cortical brain function

appear active. Dreaming is associated closely with REM sleep, and when a person is

awakened from REM, alertness returns relatively quickly.

15